Literature DB >> 9847358

Herpes simplex virus type 1 vector-mediated expression of nerve growth factor protects dorsal root ganglion neurons from peroxide toxicity.

W F Goins1, K A Lee, J D Cavalcoli, M E O'Malley, S T DeKosky, D J Fink, J C Glorioso.   

Abstract

Nerve growth factor beta subunit (beta-NGF) transgene delivery and expression by herpes simplex virus type 1 (HSV-1) vectors was examined in a cell culture model of neuroprotection from hydrogen peroxide toxicity. Replication-competent (tk- K mutant background) and replication-defective (ICP4(-);tk- S mutant background) vectors were engineered to contain the murine beta-NGF cDNA under transcriptional control of either the human cytomegalovirus immediate-early gene promoter (HCMV IEp) (e.g., KHN and SHN) or the latency-active promoter 2 (LAP2) (e.g., KLN and SLN) within the viral thymidine kinase (tk) locus. Infection of rat B103 and mouse N2A neuronal cell lines, 9L rat glioma cells, and Vero cells with the KHN or SHN vectors resulted in the production of beta-NGF-specific transcripts and beta-NGF protein reaching a maximum at 3 days postinfection (p.i.). NGF protein was released into the culture media in amounts ranging from 10.83 to 352.86 ng/ml, with the highest levels being achieved in B103 cells, and was capable of inducing neurite sprouting of PC-12 cells. The same vectors produced high levels of NGF in primary dorsal root ganglion (DRG) cultures at 3 days. In contrast to HCMV IEp-mediated expression, the LAP2-NGF vectors showed robust expression in primary DRG neurons at 14 days. The neuroprotective effect of vector produced NGF was assessed by its ability to inhibit hydrogen peroxide-induced neuron toxicity in primary DRG cultures. Consistent with the kinetics of vector-mediated NGF expression, HCMV-NGF vectors were effective in abrogating the toxic effects of peroxide at 3 but not 14 days p.i. whereas LAP2-NGF vector transduction inhibited apoptosis in DRG neurons at 14 days p.i. but was ineffective at 3 days p.i. Similar kinetics of NGF expression were observed with the KHN and KLN vectors in latently infected mouse trigeminal ganglia, where high levels of beta-NGF protein expression were detected at 4 wks p.i. only from the LAP2; HCMV-NGF-driven expression peaked at 3 days but could not be detected during HSV latency at 4 weeks. Together, these results indicate that (i) NGF vector-infected cells produce and secrete mature, biologically active beta-NGF; (ii) vector-synthesized NGF was capable of blocking peroxide-induced apoptosis in primary DRG cultures; and (iii) the HCMV-IEp functioned to produce high levels of NGF for several days; but (iv) only the native LAP2 was capable of long-term expression of a therapeutic gene product in latently infected neurons in vivo.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9847358      PMCID: PMC103859     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  125 in total

1.  Latent herpes simplex virus type 1 DNA contains two copies of the virion DNA joint region.

Authors:  D L Rock; N W Fraser
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

2.  Activation of the major immediate early gene of human cytomegalovirus by cis-acting elements in the promoter-regulatory sequence and by virus-specific trans-acting components.

Authors:  M F Stinski; T J Roehr
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

Review 3.  Physiology of nerve growth factor.

Authors:  H Thoenen; Y A Barde
Journal:  Physiol Rev       Date:  1980-10       Impact factor: 37.312

4.  Techniques in the tissue culture of rat sympathetic neurons.

Authors:  M I Johnson; V Argiro
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Promoter-regulatory region of the major immediate early gene of human cytomegalovirus.

Authors:  D R Thomsen; R M Stenberg; W F Goins; M F Stinski
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

6.  The 9L rat brain tumor: description and application of an animal model.

Authors:  M Weizsaecker; D F Deen; M L Rosenblum; T Hoshino; P H Gutin; M Barker
Journal:  J Neurol       Date:  1981       Impact factor: 4.849

7.  Isolation and nucleotide sequence of a cDNA encoding the precursor of mouse nerve growth factor.

Authors:  J Scott; M Selby; M Urdea; M Quiroga; G I Bell; W J Rutter
Journal:  Nature       Date:  1983-04-07       Impact factor: 49.962

8.  Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor.

Authors:  L A Greene; A S Tischler
Journal:  Proc Natl Acad Sci U S A       Date:  1976-07       Impact factor: 11.205

9.  Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4.

Authors:  N A DeLuca; A M McCarthy; P A Schaffer
Journal:  J Virol       Date:  1985-11       Impact factor: 5.103

10.  Nerve growth factor prevents the death and stimulates the neuronal differentiation of clonal PC12 pheochromocytoma cells in serum-free medium.

Authors:  L A Greene
Journal:  J Cell Biol       Date:  1978-09       Impact factor: 10.539

View more
  20 in total

1.  Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry.

Authors:  D B Anderson; S Laquerre; K Ghosh; H P Ghosh; W F Goins; J B Cohen; J C Glorioso
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 2.  HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications.

Authors:  A Jacobs; X O Breakefield; C Fraefel
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

Review 3.  Herpes simplex virus-based vectors.

Authors:  Robin Lachmann
Journal:  Int J Exp Pathol       Date:  2004-10       Impact factor: 1.925

Review 4.  Gene therapy for the treatment of chronic peripheral nervous system pain.

Authors:  William F Goins; Justus B Cohen; Joseph C Glorioso
Journal:  Neurobiol Dis       Date:  2012-06-02       Impact factor: 5.996

Review 5.  Methods for gene transfer to the central nervous system.

Authors:  Boris Kantor; Rachel M Bailey; Keon Wimberly; Sahana N Kalburgi; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

6.  Expression of brain-derived neurotrophic factor in the central nervous system of mice using a poliovirus-based vector.

Authors:  Qingmei Jia; Fengyi Liang; Seii Ohka; Akio Nomoto; Tsutomu Hashikawa
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

Review 7.  Herpes simplex viral vectors: late bloomers with big potential.

Authors:  Joseph C Glorioso
Journal:  Hum Gene Ther       Date:  2014-02       Impact factor: 5.695

Review 8.  Gene therapy for the treatment of diabetic neuropathy.

Authors:  Marina Mata; Munmun Chattopadhyay; David J Fink
Journal:  Curr Diab Rep       Date:  2008-12       Impact factor: 4.810

9.  Effects of herpes simplex virus vector-mediated enkephalin gene therapy on bladder overactivity and nociception.

Authors:  Hitoshi Yokoyama; Tomohiko Oguchi; William F Goins; James R Goss; Osamu Nishizawa; William C de Groat; Darren Wolfe; David M Krisky; Joseph C Glorioso; Naoki Yoshimura
Journal:  Hum Gene Ther       Date:  2013-02-14       Impact factor: 5.695

10.  Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells.

Authors:  Arvind Kumar; Tryambak D Singh; Santosh K Singh; Satya Prakash
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.